ALNY
ALNYLAM PHARMACEUTICALS, INC.Company Information
- Company Name
- ALNYLAM PHARMACEUTICALS, INC.
- CIK
- CIK0001178670
- Category
- Large accelerated filer
- Ticker: Exchange
- ALNY: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ALNY
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-10-17
- Last sale
- 2026-06-01
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 207,364
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 126,424,158
- Shares outstanding
- 133,606,000
- Ownership
- 94.62%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1,708 | 1,657 | 1,490 | 1,114 | 1,020 | 966 | 1,100 | 968 | 682 | 813 | 1,033 | ||||||
| Available For Sale Securities Debt Securities Current | 1,600 | 1,251 | 1,234 | 1,744 | 1,605 | 1,720 | 1,672 | 1,646 | 1,678 | 1,616 | 1,363 | ||||||
| Equity Securities Fv Ni | - | 0 | 0 | 0 | 7 | 8 | 8 | 10 | 11 | 11 | 10 | ||||||
| Accounts Receivable Net Current | 913 | 778 | 965 | 567 | 418 | 405 | 354 | 309 | 321 | 328 | 325 | ||||||
| Inventory Net | 97 | 83 | 75 | 72 | 66 | 79 | 76 | 84 | 94 | 89 | 96 | ||||||
| Prepaid Expense And Other Assets Current | 302 | 282 | 188 | 147 | 152 | 117 | 145 | 155 | 202 | 126 | 158 | ||||||
| Assets Current | 4,620 | 4,051 | 3,953 | 3,644 | 3,268 | 3,295 | 3,355 | 3,173 | 2,989 | 2,983 | 2,985 | ||||||
| Property Plant And Equipment Net | 554 | 513 | 502 | 500 | 499 | 503 | 507 | 517 | 523 | 526 | 526 | ||||||
| Operating Lease Right Of Use Asset | 183 | 195 | 191 | 192 | 197 | 191 | 196 | 198 | 195 | 200 | 203 | ||||||
| Deferred Income Tax Assets Net | 114 | 126 | 99 | 104 | 107 | 117 | - | - | - | 10 | - | ||||||
| Restricted Investments Noncurrent | 22 | 22 | 51 | 69 | 69 | 69 | 69 | 49 | 49 | 49 | 49 | ||||||
| Other Assets Noncurrent | 65 | 59 | 56 | 57 | 74 | 65 | 78 | 72 | 67 | 62 | 75 | ||||||
| Assets | 5,559 | 4,966 | 4,852 | 4,566 | 4,214 | 4,240 | 4,205 | 4,010 | 3,824 | 3,830 | 3,839 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable Current | 108 | 116 | 118 | 102 | 97 | 88 | 71 | 74 | 78 | 56 | 74 | ||||||
| Accrued Liabilities Current | 1,096 | 1,080 | 1,154 | 919 | 704 | 794 | 946 | 809 | 699 | 713 | 713 | ||||||
| Operating Lease Liability Current | 46 | 46 | 45 | 46 | 46 | 42 | 42 | 42 | 42 | 42 | 42 | ||||||
| Contract With Customer Liability Current | 4 | 5 | 3 | 15 | 28 | 55 | 71 | 69 | 77 | 103 | 77 | ||||||
| Derivative Liabilities Current | - | 0 | 121 | 121 | 118 | 94 | - | - | - | - | - | ||||||
| Liabilities Current | 1,513 | 1,466 | 1,555 | 1,301 | 1,076 | 1,186 | 1,221 | 1,055 | 942 | 968 | 950 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | 0 | 1 | 2 | 186 | 188 | 196 | ||||||
| Operating Lease Liability Noncurrent | 210 | 225 | 223 | 224 | 230 | 230 | 236 | 239 | 238 | 243 | 248 | ||||||
| Convertible Debt Noncurrent | 1,011 | 1,008 | 1,040 | 1,027 | 1,026 | 1,025 | 1,024 | 1,023 | 1,022 | 1,021 | 1,020 | ||||||
| Derivative Liabilities Noncurrent | - | 0 | 440 | 408 | 422 | 393 | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 9 | 8 | 10 | 11 | 6 | 5 | 357 | 350 | 320 | 308 | 281 | ||||||
| Liabilities | 4,205 | 4,177 | 4,618 | 4,315 | 4,098 | 4,173 | 4,173 | 4,013 | 4,044 | 4,051 | 4,005 | ||||||
| Preferred Stock Value Outstanding | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
Stockholders Equity | |||||||||||||||||
| Common Stock Value Outstanding | - | - | - | - | - | - | - | - | - | 1 | - | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 7,717 | 7,510 | 7,415 | 7,691 | 7,497 | 7,388 | 7,260 | 7,123 | 6,882 | 6,811 | 6,737 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -32 | -20 | -22 | -30 | -38 | -35 | -25 | -35 | -27 | -23 | -32 | ||||||
| Retained Earnings Accumulated Deficit | -6,332 | -6,703 | -7,160 | -7,412 | -7,345 | -7,288 | -7,204 | -7,092 | -7,076 | -7,010 | -6,872 | ||||||
| Stockholders Equity | 1,354 | 789 | 234 | 555 | 115 | 67 | 32 | -3 | -219 | -221 | -166 | ||||||
| Liabilities And Stockholders Equity | 5,559 | 4,966 | 4,852 | 4,566 | 4,214 | 4,240 | 4,205 | 4,010 | 3,824 | 3,830 | 3,839 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 134 | 132 | 132 | 131 | 130 | 129 | 129 | 128 | 126 | 126 | 125 | ||||||
| Shares Outstanding | 134 | 132 | 132 | 131 | 130 | 129 | 129 | 128 | 126 | 126 | 125 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialALNYLAM PHARMACEUTICALS, INC. (ALNY) — SEC Financial Statements & Analysis
ALNYLAM PHARMACEUTICALS, INC. (ALNY) is a pharmaceutical preparations company. ALNYLAM PHARMACEUTICALS, INC. trades on Nasdaq as: ALNY. ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, ALNYLAM PHARMACEUTICALS, INC. carries a market cap of $40.22B, a P/E ratio of 75.08x, a P/B ratio of 29.70x, a P/S ratio of 9.12x, an enterprise value of $39.52B, and an EV/EBITDA multiple of 50.43x. On profitability, it posts a gross margin of 79.48%, an operating margin of 16.21%, a net margin of 12.15%, a Return on Equity (ROE) of 72.91%, a Return on Assets (ROA) of 10.96%, and a Return on Invested Capital (ROIC) of 151.47%. Per share, it reports EPS of $4.01, diluted EPS of $3.87, free cash flow per share of $6.99, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 87.84% year-over-year, net income growth of -298.63% year-over-year, and EPS growth of -292.79% year-over-year. On the balance sheet, it maintains a current ratio of 3.05x, a quick ratio of 2.79x, working capital of $3.11B, a debt-to-equity ratio of 3.11x, a debt ratio of 0.76, an interest coverage ratio of 2.42x, free cash flow of $933.38M (TTM), and net debt of $-698.50M. Figures sourced from SEC EDGAR.
- Market Cap
- $40.22B
- P/E TTM
- 75.08x
- EPS TTM
- $4.01
- P/B TTM
- 29.70x
- ROE TTM
- 72.91%
- ROA TTM
- 10.96%
- Debt To Equity
- 3.11x
- Free Cash Flow TTM
- $933.38M
- Net Revenue TTM Growth 1Y
- 87.84%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ALNYLAM PHARMACEUTICALS, INC. in?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) operates in the Pharmaceutical Preparations industry.
What exchange does ALNY trade on?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) trades on the Nasdaq.
When was ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s most recent SEC filing?
ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is ALNY's market cap?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a market capitalization of $40.22B as of 2026-06-30.
What is ALNY's P/E ratio?
ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s trailing twelve month P/E ratio is 75.08x as of 2026-06-30.
What is ALNY's EPS (earnings per share)?
ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s trailing twelve month EPS is $4.01 as of 2026-06-30.
What is ALNY's ROE (return on equity)?
ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s trailing twelve month Return on Equity (ROE) is 72.91% as of 2026-06-30.
What is ALNY's ROA (return on assets)?
ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s trailing twelve month Return on Assets (ROA) is 10.96% as of 2026-06-30.
What is ALNY's ROIC (return on invested capital)?
ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s trailing twelve month Return on Invested Capital (ROIC) is 151.47% as of 2026-06-30.
What is ALNY's EV/EBITDA?
ALNYLAM PHARMACEUTICALS, INC. (ALNY)'s trailing twelve month EV/EBITDA is 50.43x as of 2026-06-30.